placebo-controlled clinical trial designed to compare the efficacy and safety of molgramostim 300 mcg self-administered once daily by inhalation with matching placebo in patients with aPAP.

Vice Presidential candidate for the main opposition National Democratic Congress (NDC), Professor Naana Jane Opoku-Agyemang, has vowed to tackle corruption in the distribution of premix fuel and ...

Universal Basic Income (UBI) has frequently been discussed as a potential solution to economic inequality in an increasingly automated and AI-driven world. Alternatives like Universal Basic ...

Rights group Pusat Komas linked the government's inconsistent actions to the ongoing racial and religious tensions in the country. The group stated that the government's approach has been mixed ...

By the year’s close, the garden’s visitors were looking on in bemusement as a team of scientists at the University of Central Lancashire installed a promising solution: A permeable concrete ...

Her question sparked a flood of suggestions, but the standout solution was a DIY mix of white vinegar, salt, and washing-up liquid, reports the Express. Michelle Thompson recommended: "White wine ...

GLUGGING on the go is all the rage, with recent figures showing a 60 per cent surge in sales of canned pre-mixed cocktails. Favourites include passion fruit martinis and mojitos, with celebrities ...

The increasing incidence of respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD) is a significant driver for the Albuterol Sulfate Inhalation Aerosol market.

Our lead program, molgramostim nebulizer solution, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).